Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Zevalin mentioned as an ADC drug being sold in the market. Funny, I never thought as Zevalin as an ADC (antibody-drug conjugate) but when you think about it, it is. The article is about ADC biotech Mersana's IPO and mentions other ADC drugs

There are now a handful of ADCs on the market—notably Roche's HER2-targeting breast cancer therapy Kadcyla, Seattle Genetics' Adcetris for classical Hodgkin lymphoma and Spectrum Pharma's non-Hodgkin lymphoma (NHL) drug Zevalin—and well upwards of 200 candidates in clinical development.

Ha, Zevalin, the original ADC!

ps A couple of posts back, I mentioned that I thought that Kadcyla (aka T-DM1) will be doing a combo trial with Spectrum's poziotinib which makes me think of 6 degrees of separation for some reason.

ps ps This article also mentions that Mersano's drug starting clinical trials in animal models is active where Kadcycla is not. I think that would be an incentive for Genentech to get things moving with the combo trial.

Mersana's lead drug has been pitted against $800m-plus brand Kadcyla in animal models and shown durable tumor regressions where Roche's drug is inactive, according to the company.

http://www.fiercebiotech.com/biotech/mersana-takes-ipo-plunge-seeking-75m-to-push-its-antibody-drug-conjugates?mkt_tok=eyJpIjoiTkdNMFlUazVNamMwWlRVeiIsInQiOiJKTlFjbStubGNvS3Fid2k1bE15V1pcL1B4YXA0aFZWMmFXVzBpdFNxb3NwR0NsdHF5c2ZzN0JERFhUZ2VXVjZvRmVDVGNCZ0paSjFUbHNUUWd3alNVMEFjcENiTERjdjdmdGg3S1FJOVwvNmxubFwvSkJSRW40QnBcL2tVQjNIQkJJcmgifQ%3D%3D&mrkid=899996&utm_medium=nl&utm_source=internal